Rigel Pharmaceuticals Inc (RIGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $837.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
Rigel Pharmaceuticals Inc (RIGL) Earnings: Report Dates and Results
Rigel Pharmaceuticals (RIGL) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Rigel Pharmaceuticals reported EPS of $0.65, below the $0.87 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RIGL has an expected report date of Mar 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.1% below the $1.12 reported for the quarter ended Dec 31, 2025.
RIGL Earnings Call
The latest RIGL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, RIGL beat 23, missed 11 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $80.89M, up 16.5% from $69.46M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.65 | $0.87 | $0.77 - $1.07 | -25.29% | Miss | -55.5% | 4 | N/A | Nov 5, 2026 | $80.89M |
| Jun 30, 2026 | $0.88 | $0.91 | -$2.66 - $1.11 | -3.30% | Miss | -73.2% | 4 | 0 up, 0 down | Aug 4, 2026 | $78.70M |
| Mar 31, 2026 | $0.44 | $0.87 | $0.57 - $1.10 | -49.43% | Miss | -30.2% | 3 | 0 up, 1 down | May 5, 2026 | $58.82M |
| Dec 31, 2025 | $1.12 | $1.20 | $1.02 - $1.34 | -6.80% | Miss | +40.0% | 5 | 2 up, 1 down | Mar 3, 2026 | $69.80M |
| Sep 30, 2025 | $1.46 | $0.94 | $0.68 - $1.08 | +55.32% | Beat | +108.6% | 5 | 1 up, 0 down | Nov 4, 2025 | $69.46M |
| Jun 30, 2025 | $3.28 | $1.41 | $0.14 - $2.78 | +132.62% | Beat | N/A | 4 | 1 up, 0 down | Aug 5, 2025 | $101.69M |
| Mar 31, 2025 | $0.63 | $0.09 | -$0.08 - $0.37 | +600.00% | Beat | N/A | 5 | 0 up, 0 down | May 6, 2025 | $53.33M |
| Dec 31, 2024 | $0.80 | $0.58 | $0.13 - $1.10 | +38.19% | Beat | +18947.6% | 5 | 0 up, 0 down | Mar 4, 2025 | $57.60M |
| Sep 30, 2024 | $0.70 | $0.06 | -$0.21 - $0.32 | N/A | N/A | N/A | 6 | 0 up, 0 down | Nov 7, 2024 | $55.31M |
| Jun 30, 2024 | -$0.06 | -$0.18 | -$0.50 - -$0.13 | +66.67% | Beat | N/A | 5 | 0 up, 0 down | Aug 6, 2024 | $36.84M |
| Mar 31, 2024 | -$0.50 | -$0.27 | -$0.40 - -$0.10 | -85.19% | Miss | N/A | 6 | 0 up, 0 down | May 7, 2024 | $29.53M |
| Dec 31, 2023 | $0.00 | -$0.03 | -$0.05 - -$0.01 | +114.00% | Beat | -58.0% | 5 | 0 up, 0 down | Mar 5, 2024 | $35.79M |
| Sep 30, 2023 | -$0.30 | -$0.66 | -$0.90 - -$0.60 | +54.55% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2023 | $28.13M |
| Jun 30, 2023 | -$0.40 | -$0.80 | -$0.90 - -$0.70 | +50.00% | Beat | N/A | 6 | 0 up, 0 down | Aug 1, 2023 | $26.89M |
| Mar 31, 2023 | -$0.80 | -$0.93 | -$1.20 - -$0.70 | +13.98% | Beat | N/A | 6 | 0 up, 0 down | May 2, 2023 | $26.07M |
| Dec 31, 2022 | $0.01 | -$0.11 | -$0.20 - $0.02 | +109.09% | Beat | N/A | 6 | 0 up, 0 down | Mar 7, 2023 | $51.28M |
| Sep 30, 2022 | -$1.10 | -$1.36 | -$1.60 - -$1.20 | +19.12% | Beat | N/A | 7 | 1 up, 0 down | Nov 3, 2022 | $22.41M |
| Jun 30, 2022 | -$0.80 | -$1.21 | -$1.40 - -$1.10 | +33.88% | Beat | N/A | 7 | 0 up, 0 down | Aug 2, 2022 | $29.82M |
| Mar 31, 2022 | -$1.60 | -$1.36 | -$1.80 - -$1.10 | -17.65% | Miss | -172.7% | 7 | 0 up, 0 down | May 3, 2022 | $16.73M |
| Dec 31, 2021 | -$0.13 | -$0.13 | -$0.13 - -$0.10 | 0.00% | In line | N/A | 6 | N/A | Mar 1, 2022 | $20.41M |
| Sep 30, 2021 | -$1.20 | -$1.00 | -$1.30 - -$0.70 | -20.00% | Miss | N/A | 6 | N/A | Nov 2, 2021 | $21.54M |
| Jun 30, 2021 | -$0.80 | -$1.15 | -$1.30 - -$1.00 | +30.43% | Beat | N/A | 6 | N/A | Aug 3, 2021 | $26.27M |
| Mar 31, 2021 | $2.20 | $0.30 | -$1.30 - $2.60 | +633.33% | Beat | +1592.3% | 6 | N/A | May 5, 2021 | $81.02M |
| Dec 31, 2020 | -$0.11 | -$0.11 | -$0.16 - -$0.09 | 0.00% | In line | N/A | 6 | N/A | Mar 2, 2021 | $18.45M |
| Sep 30, 2020 | -$0.80 | -$1.22 | -$1.40 - -$1.10 | +34.43% | Beat | N/A | 7 | N/A | Nov 5, 2020 | $18.39M |
| Jun 30, 2020 | -$1.00 | -$1.33 | -$1.50 - -$1.20 | +24.81% | Beat | N/A | 7 | N/A | Aug 4, 2020 | $16.02M |
| Mar 31, 2020 | $0.13 | $0.13 | $0.12 - $0.14 | 0.00% | In line | N/A | 7 | N/A | May 5, 2020 | $55.76M |
| Dec 31, 2019 | -$1.00 | -$0.85 | -$1.40 - $1.30 | -17.65% | Miss | -3433.3% | 7 | N/A | Feb 27, 2020 | $15.40M |
| Sep 30, 2019 | -$0.70 | -$1.07 | -$1.40 - -$0.70 | +34.58% | Beat | N/A | 7 | N/A | Nov 5, 2019 | $20.86M |
| Jun 30, 2019 | -$1.20 | -$1.37 | -$1.50 - -$1.20 | +12.41% | Beat | N/A | 7 | N/A | Aug 6, 2019 | $10.41M |
| Mar 31, 2019 | -$1.10 | -$1.28 | -$1.60 - -$1.20 | +14.06% | Beat | N/A | 7 | N/A | May 7, 2019 | $12.62M |
| Dec 31, 2018 | $0.03 | $0.03 | $0.03 - $0.04 | 0.00% | In line | N/A | 7 | N/A | Feb 28, 2019 | $37.86M |
| Sep 30, 2018 | -$1.40 | -$1.50 | -$1.70 - -$1.30 | +6.67% | Beat | N/A | 7 | N/A | Nov 6, 2018 | $4.87M |
| Jun 30, 2018 | -$1.60 | -$1.62 | -$1.70 - -$1.60 | +1.23% | Beat | N/A | 6 | N/A | Aug 8, 2018 | $1.79M |
| Mar 31, 2018 | -$1.70 | -$1.70 | -$1.80 - -$1.60 | 0.00% | In line | N/A | 4 | N/A | May 1, 2018 | N/A |
| Dec 31, 2017 | -$0.18 | -$0.13 | -$0.14 - -$0.12 | -38.46% | Miss | N/A | 6 | N/A | Mar 6, 2018 | $3.58M |
| Sep 30, 2017 | -$1.40 | -$1.53 | N/A | +8.50% | Beat | N/A | 2 | N/A | Nov 7, 2017 | $900000 |
| Jun 30, 2017 | -$1.60 | -$1.50 | -$1.50 - -$1.40 | -6.67% | Miss | N/A | 4 | N/A | Aug 1, 2017 | N/A |
| Mar 31, 2017 | -$1.41 | -$1.08 | N/A | -30.56% | Miss | N/A | N/A | N/A | May 2, 2017 | $3.58M |
| Dec 31, 2016 | -$0.16 | -$0.17 | N/A | +5.88% | Beat | N/A | N/A | N/A | Mar 7, 2017 | $3.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.49, up 590.4% from the year before. It was -$5.36 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.49 | +590.4% |
| Dec 31, 2024 | $0.94 | N/A |
| Dec 31, 2023 | -$1.50 | N/A |
| Dec 31, 2022 | -$3.49 | -5085.7% |
| Dec 31, 2021 | $0.07 | N/A |
| Dec 31, 2020 | -$1.78 | N/A |
| Dec 31, 2019 | -$4.00 | N/A |
| Dec 31, 2018 | -$4.67 | N/A |
| Dec 31, 2017 | -$4.59 | N/A |
| Dec 31, 2016 | -$5.36 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,800 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,794 | 11 | |
| 2026Q2 | Jun 30, 2026 | 6,525 | 9 | |
| 2026Q1 | Mar 31, 2026 | 5,319 | 10 | |
| 2025Q4 | Dec 31, 2025 | 6,220 | 11 | |
| 2025Q3 | Sep 30, 2025 | 4,998 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,454 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,108 | 9 | |
| 2024Q4 | Dec 31, 2024 | 7,270 | 11 |
2026Q3 Earnings Call
Opening remarks
Raymond Furey Executive Vice President, General Counsel and Corporate Secretary Thank you. Welcome to our third quarter 2026 financial results conference call. The financial press release for the third quarter 2026 was issued earlier today and can be viewed along with the slides for this presentation in the News & Events section of our Investor Relations site on rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for commercial, regulatory, product development and other business activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31, 2025, on file with the SEC, and subsequent filings with the SEC, including our Q3 quarterly report on Form 10-Q with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances except as required by law. At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul?
Raul Rodriguez President and Chief Executive Officer Thank you, Ray, and thank you all for joining us today. Also joining me on the call are Dave Santos, our Chief Commercial Officer; Dr. Alison Hannah, our Chief Medical Officer; and Dean Schorno, our Chief Financial Officer. Before we begin, I'd like to share a few key highlights from the quarter. We delivered over $72 million in net product sales, our highest ever, and another profitable quarter. This was while taking important steps towards Rigel's next phase of growth. VEPPANU, Rigel's fourth commercial product, is now available in the U.S. with an encouraging start to its launch, and we continue to advance R289 towards its next stage of development. I'll start with an overview of this progress before the team takes you through the details. Moving to Slide 4. VEPPANU became commercially available in the U.S. on August 13 and generated $6.6 million in net product sales through the end of the third quarter. Following the close of the global in-license agreement in June, our team moved quickly to initiate launch activities, leveraging our established commercial and medical infrastructure to engage physicians and build awareness ahead of commercial availability. Within just 2 months of closing the transaction, VEPPANU was successfully integrated into our existing distribution network and ready for commercial launch. During Q3, we shipped VEPPANU to over 100 patients and clinics. Encouragingly, the majority of the patients who received VEPPANU during the early weeks of launch had already refilled their prescriptions by quarter end.
Frequently Asked Questions About RIGL
When is Rigel Pharmaceuticals's next earnings date?
Rigel Pharmaceuticals's next earnings report is expected for Mar 1, 2027.
Did RIGL beat earnings estimates last quarter?
No. Rigel Pharmaceuticals reported EPS of $0.65 for the quarter ended Sep 30, 2026, below the $0.87 estimate by 25.29%.
What EPS do analysts expect from RIGL next quarter?
The consensus EPS estimate for Rigel Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.94 from 7 analysts, with estimates from $0.85 to $1.06.
How often does RIGL beat earnings estimates?
Rigel Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +92.67%.
RIGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors